Endothelial Activation and Stress Index (EASIX): A Prognostic Marker for Mortality After Acute Graft-Versus-Host Disease and Endothelial Complications.

Thomas Luft

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas LuftInternal Medicine V, Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. Thomas.Luft@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute graft-versus-host disease (aGVHD) is a potentially life-threatening complication after allogeneic stem cell transplantation (alloSCT) commonly treated with steroids. Steroid-refractory aGVHD is associated with thrombotic microangiopathy (TAM), supporting the notion of endothelial dysfunction as a risk factor for poor prognosis. Several diagnostic criteria exist to diagnose TAM; however, emerging data points to the clinical importance of the endothelial activation and stress index (EASIX) as biomarker in the context of alloSCT. The EASIX integrates three basic lab parameters (serum lactate dehydrogenase and creatinine concentrations with platelet counts) into one ratio that produces continuous values to allow monitoring of impending endothelial complications after alloSCT. This chapter provides an overview of the use of EASIX as prognostic marker for mortality after aGVHD and endothelial complications.

Indexed as

BiomarkersEndothelium, VascularGraft vs Host DiseaseThrombotic MicroangiopathiesAcute DiseaseCreatinineHematopoietic Stem Cell TransplantationHumansL-Lactate DehydrogenasePrognosisTransplantation, HomologousBiomarkersCreatinineL-Lactate DehydrogenaseAcute GVHDAllogeneic stem cell transplantationAtypical hemolytic uremic syndromesCreatinineEndothelial activation and stress indexLactate dehydrogenase plateletsSepsisSteroid-refractory GVHDThrombotic microangiopathy

Identifiers

PMID40100594

DOI10.1055/s-0030-1253445

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.